163 related articles for article (PubMed ID: 38410201)
1. Preparation of hepatocellular carcinoma mRNA vaccines based on potential tumor targets and immunophenotypes.
Wang HK; Xu XH; Wang SM; Zhang HY
Transl Cancer Res; 2024 Jan; 13(1):173-190. PubMed ID: 38410201
[TBL] [Abstract][Full Text] [Related]
2. Identification of tumor antigens and immune subtypes of hepatocellular carcinoma for mRNA vaccine development.
Lu TL; Li CL; Gong YQ; Hou FT; Chen CW
World J Gastrointest Oncol; 2023 Oct; 15(10):1717-1738. PubMed ID: 37969406
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Analyses of Immune Subtypes of Stomach Adenocarcinoma for mRNA Vaccination.
You W; Ouyang J; Cai Z; Chen Y; Wu X
Front Immunol; 2022; 13():827506. PubMed ID: 35874675
[TBL] [Abstract][Full Text] [Related]
4. Identifying Potential Tumor Antigens and Antigens-Related Subtypes in Hepatocellular Carcinoma for mRNA Vaccine Development.
Liao W; Shi Z; Tang H; Wu T; Zhang C; He Y; Zou R; Wang L
J Oncol; 2022; 2022():6851026. PubMed ID: 36072981
[TBL] [Abstract][Full Text] [Related]
5. Immune signature-based hepatocellular carcinoma subtypes may provide novel insights into therapy and prognosis predictions.
Zheng Q; Yang Q; Zhou J; Gu X; Zhou H; Dong X; Zhu H; Chen Z
Cancer Cell Int; 2021 Jun; 21(1):330. PubMed ID: 34193146
[TBL] [Abstract][Full Text] [Related]
6. Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development.
Huang X; Zhang G; Tang T; Liang T
Mol Cancer; 2021 Mar; 20(1):44. PubMed ID: 33648511
[TBL] [Abstract][Full Text] [Related]
7. Hypoxic Characteristic in the Immunosuppressive Microenvironment of Hepatocellular Carcinoma.
Mo Z; Liu D; Rong D; Zhang S
Front Immunol; 2021; 12():611058. PubMed ID: 33679749
[No Abstract] [Full Text] [Related]
8. Dissection of tumor antigens and immune landscape in clear cell renal cell carcinoma: Preconditions for development and precision medicine of mRNA vaccine.
Hu J; Mo Z
Math Biosci Eng; 2023 Jan; 20(2):2157-2182. PubMed ID: 36899527
[TBL] [Abstract][Full Text] [Related]
9. Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development.
Ma S; Ba Y; Ji H; Wang F; Du J; Hu S
Front Immunol; 2021; 12():738435. PubMed ID: 34603319
[TBL] [Abstract][Full Text] [Related]
10. Tumor antigens and immune subtypes of glioblastoma: the fundamentals of mRNA vaccine and individualized immunotherapy development.
Wu C; Qin C; Long W; Wang X; Xiao K; Liu Q
J Big Data; 2022; 9(1):92. PubMed ID: 35855914
[TBL] [Abstract][Full Text] [Related]
11. Discovery and characterization of tumor antigens in hepatocellular carcinoma for mRNA vaccine development.
Fu J; Chen F; Lin Y; Gao J; Chen A; Yang J
J Cancer Res Clin Oncol; 2023 Jul; 149(7):4047-4061. PubMed ID: 36038676
[TBL] [Abstract][Full Text] [Related]
12. Novel Molecular Subtyping Scheme Based on In Silico Analysis of Cuproptosis Regulator Gene Patterns Optimizes Survival Prediction and Treatment of Hepatocellular Carcinoma.
Jiang H; Chen H; Wang Y; Qian Y
J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762710
[TBL] [Abstract][Full Text] [Related]
13. Bioinformatics analyses for the identification of tumor antigens and immune subtypes of gastric adenocarcinoma.
Wei S; Sun Q; Chen J; Li X; Hu Z
Front Genet; 2022; 13():1068112. PubMed ID: 36579327
[No Abstract] [Full Text] [Related]
14. Identification of Tumor Antigens and Immune Subtypes of Esophageal Squamous Cell Carcinoma for mRNA Vaccine Development.
Lu T; Xu R; Wang CH; Zhao JY; Peng B; Wang J; Zhang LY
Front Genet; 2022; 13():853113. PubMed ID: 35734437
[No Abstract] [Full Text] [Related]
15. N6-methyladenosine (m6A) RNA methylation regulator SNRPC is a prognostic biomarker and is correlated with immunotherapy in hepatocellular carcinoma.
Cai J; Zhou M; Xu J
World J Surg Oncol; 2021 Aug; 19(1):241. PubMed ID: 34389000
[TBL] [Abstract][Full Text] [Related]
16. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
Gao S; Zhang L; Wang H
Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
[TBL] [Abstract][Full Text] [Related]
17. Identification of tumor-specific neoantigens and immune clusters of hepatocellular carcinoma for mRNA vaccine development.
Li YF; Hou QQ; Zhao S; Chen X; Tang M; Li L
J Cancer Res Clin Oncol; 2023 Feb; 149(2):623-637. PubMed ID: 36239794
[TBL] [Abstract][Full Text] [Related]
18. Dissecting Tumor Antigens and Immune Subtypes of Glioma to Develop mRNA Vaccine.
Zhong H; Liu S; Cao F; Zhao Y; Zhou J; Tang F; Peng Z; Li Y; Xu S; Wang C; Yang G; Li ZQ
Front Immunol; 2021; 12():709986. PubMed ID: 34512630
[TBL] [Abstract][Full Text] [Related]
19. Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development.
Lin H; Wang K; Xiong Y; Zhou L; Yang Y; Chen S; Xu P; Zhou Y; Mao R; Lv G; Wang P; Zhou D
Front Immunol; 2022; 13():773264. PubMed ID: 35185876
[TBL] [Abstract][Full Text] [Related]
20. Identification of three tumor antigens and immune subtypes for mRNA vaccine development in diffuse glioma.
Zhou Q; Yan X; Zhu H; Xin Z; Zhao J; Shen W; Yin W; Guo Y; Xu H; Zhao M; Liu W; Jiang X; Ren C
Theranostics; 2021; 11(20):9775-9790. PubMed ID: 34815785
[No Abstract] [Full Text] [Related]
[Next] [New Search]
